Virios therapeutics announces first quarter 2023 financial results

Atlanta, may 11, 2023 (globe newswire) -- virios therapeutics, inc. (nasdaq: viri) (the “company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“fm”), today announced financial results for the first quarter ended march 31, 2023.

VIRI Ratings Summary

VIRI Quant Ranking